GDC-0834 is a potent, selective, and irreversible inhibitor of Bruton's tyrosine kinase (BTK), primarily investigated for the treatment of autoimmune diseases such as rheumatoid arthritis (RA). BTK is essential for B-cell activation and immune signaling pathways involved in inflammation. Preclinical studies demonstrated its potential to reduce joint inflammation and disease progression in RA models. However, clinical development was discontinued due to challenges with metabolic stability, including rapid conjugation with glutathione leading to poor pharmacokinetics. Today, GDC-0834 serves as a valuable research tool for studying BTK signaling, developing next-generation inhibitors, and exploring applications in both autoimmune disorders and B-cell malignancies like chronic lymphocytic leukemia.